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related deaths within the first 5 years. Additionally, once meta-
static, patients with TNBC have shorter overall survival (OS) in 
comparison to those with other subtypes. TNBC patients are prone 
to developing visceral metastases more often than bone metastases 
when compared to other subtypes. Generally, TNBC occurs in 
younger women. Despite the greater relative benefit of chemother-
apy (CT) in this patient population and a large number of clinical 
trials in the last decade, no optimal neo/adjuvant CT regimen has 
been identified [1–4].
Heterogeneity in TNBC
TNBC has a significant variability in pathological and morpho-
logical features with many potential molecular targets. Lehmann et 
al. [5] have proposed one of the most frequently used subclassifica-
tions, which includes 4 subtypes: 2 basal-like (BL1 and BL2), a 
mesenchymal, and a luminal androgen receptor subtype. 
Approximately 70% of TNBCs contain 20% or more tumor-in-
filtrating lymphocytes (TILs) in the tumor stroma [6]. The gener-
ally higher level of TILs and the higher expression of immune 
checkpoint molecules in TNBC compared with ER-positive (ER+) 
BCs also makes TNBC an attractive target for immunotherapy. 
Immune-rich TBNC has a more favorable prognosis.
Androgen receptor-positive TNBC accounts for approximately 
10% of all TNBCs and tends to have a more indolent course and 
share certain features with ER+ BCs, including expression of sev-
eral estrogen-regulated genes and frequent PIK3CA mutations. 
Anti-androgens are being investigated as a potential treatment in 
this subset.
Germline BRCA-mutant TNBCs represent another potential 
therapeutically relevant subtype. Germline BRCA1 and BRCA2 
mutations are more frequent in TNBC than in other BC subtypes. 
There is increasing evidence that germline BRCA-mutant BCs have 
above-average platinum sensitivity and increased sensitivity to 
poly(ADP-ribose) polymerase (PARP) inhibitors. 
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Summary
Triple-negative breast cancer (TNBC) represents a heter-
ogeneous breast cancer subtype with a poor prognosis. 
The optimal adjuvant chemotherapy regimen is still un-
known. Although numerous large randomized trials have 
established the benefit of adjuvant anthracyclines and/or 
taxanes in TNBC, there is no preferred regimen for these 
patients. There is currently no guideline. Moreover, with-
out knowing the optimal treatment backbone, it will not 
be possible to evaluate whether adding agents such as 
platinum or other novel therapies is beneficial for TNBC 
patients. Furthermore, the best duration of adjuvant 
treatment in TNBC is still unknown. This review will 
focus on results of clinical trials that analyzed the bene-
fits of extending the duration of adjuvant treatment in 
TNBCs with maintenance treatments. We will further dis-
cuss promising results in favor of other new agents in-
cluding capecitabine, metronomic treatment, and biolog-
ical drugs. 
© 2017 S. Karger GmbH, Freiburg
Introduction
Triple-negative breast cancer (TNBC) is defined by ?  1% ex-
pression of the estrogen receptor (ER) and progesterone receptor, 
and normal human epidermal growth factor receptor 2 (HER2) 
gene copy number and expression. TNBC accounts for 12–17% of 
all breast cancers (BC). TNBC has shown an increased rate of BC-
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Adjuvant Therapies for Early-Stage TNBC
The optimal adjuvant CT regimen is still unknown. A 6–9 times 
higher risk for relapse has been reported for patients with TNBC 
who do not achieve a pathologic complete response (pCR) with 
neoadjuvant treatment. Because of this strong prognostic effect, 
pCR was proposed as a surrogate for OS in these 2 BC subtypes 
[7–9]. Numerous clinical trials have been designed to test the value 
of further adjuvant therapy in TNBC patients with no pCR. Al-
though numerous large randomized trials have established the 
benefit of adjuvant anthracyclines and/or taxanes in TNBC, there 
is no preferred regimen for these patients, unlike for those with 
other BC subtypes. There is currently no guideline. Moreover, 
without knowing the optimal treatment backbone, it will not be 
possible to evaluate whether adding agents such as platinum or 
other novel therapies is beneficial for TNBC patients. There are 
promising results in favor of other new agents including capecit-
abine (X), platinum-based agents, and ixabepilone. 
Duration of Adjuvant Chemotherapy in TNBC
Several trials have addressed the question of the optimal dura-
tion of adjuvant CT for BC patients. Duration of CT might be best 
tested in patients with ER-negative (ER-) tumors, where cytotoxic 
rather than endocrine effects of CT might prevail. Although this is 
a small subset compared with the entire BC population, it might 
represent a group with particular relevance for specific treatment 
analysis pertaining to questions of adjuvant CT. 
Several trials are examining regimens that differ in duration of 
therapy but also in the drugs given. In these trials, the effects of 
treatment duration and drug choice are inextricably confounded. 
Differing conclusions about treatment duration are being reached.
CMF (cyclophosphamide, methotrexate, and fluorouracil) regi-
mens were widely used in the 1990s, and were followed by the in-
troduction of anthracycline-containing regimens and anthracy-
cline/taxane regimens as suitable options for TNBC patients. In 
1998, the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) [10] presented a meta-analysis of data from 47 ran-
domized controlled trials of prolonged poly-CT versus no CT that 
started before 1990. 1 of the 2 types of comparison between differ-
ent poly-CT regimens reviewed in this report was different dura-
tions of the same regimen. The analysis involved 6,104 women in 
11 trials and evaluated the comparison of longer versus at least 6 
months of poly-CT and longer versus less than 6 months. Overall, 
there were a non-significant 7% further reduction in recurrence 
with longer therapy and no difference in OS (1% increase). The re-
striction to women aged < 50 years did not modify these findings.
Table 1 summarizes the results of the most significant trials which 
addressed the question of the optimal duration of adjuvant CT. 
The US Intergroup trial investigating the addition of 4 cycles of 
paclitaxel following 4 cycles of AC (cyclophosphamide, doxoru-
bicin) demonstrated a small but significant improvement in dis-
ease-free survival (DFS) and OS for the longer adjusted regimen 
[11]. This improvement was observed almost exclusively among 
patients with ER- tumors who did not receive tamoxifen. T
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observed in X-treated patients. X-based combination adjuvant CT 
might provide some BCSS benefit compared with X-free regimens 
in EBC, but the absolute survival gain is small, and the survival 
benefit appears to be restricted to patients with hormone receptor-
negative EBC, which may indicate a target population for X-based 
combination adjuvant CT.
In 2015, Alagizy et al. [20], in a prospective phase II study, evalu-
ated the tolerability and efficacy of metronomic X as an extended 
adjuvant treatment for women with TNBC. The trial enrolled 41 pa-
tients between June 2010 and December 2013. The patients received 
500 mg X orally BID continuously for 6 months after 6 cycles of ad-
juvant CT with FEC100 (fluorouracil, epirubicin, cyclophospha-
mide) ± postoperative radiotherapy. The choice of giving uniform 
adjuvant CT to the patients enrolled allowed better assessment of 
the efficacy of metronomic X. The study showed that extended adju-
vant metronomic X was well tolerated with no grade 3 or 4 toxicities 
or life-threatening AEs at all. Only 6 (15%) relapse events occurred. 
The incidence of both local and distant relapses was lower in com-
parison to other studies, but a larger sample and longer follow-up 
are required for better and more mature results. The effect of lower-
dose X on DFS needs to be evaluated in a larger phase III study. 
CIBOMA 2004–01/GEICAM 2003–11 [21] is a multicenter, 
open-label, randomized phase III trial evaluating the efficacy of 
maintenance treatment with X in operable TNBC node-positive 
patients (or node-negative with a tumor diameter of ? 1 cm) who 
have received standard anthracyclines and or taxane-containing 
CT. Patients were randomized to Arm B (8 cycles of 1,000 mg/m2 
X BID, days 1–14, q21d) or the observation (Arm B). The primary 
endpoint was DFS. The first safety data, presented at the 2010 San 
Antonio Cancer Symposium [22], revealed that the safety profile of 
adjuvant X as maintenance therapy was consistent with its known 
toxicity profile. More than 75% of patients were able to continue 
their treatment as planned with approximately 15% discontinuing 
due to toxicity or withdrawal. Grade 3/4 AEs were higher with 
maintenance X: HFS 17.4%, diarrhea 2.9%, vomiting 1.0%, and el-
evated bilirubin 1.0%. 
SYSUCC-001 [23] is an open-label, randomized phase III trial 
evaluating the efficacy of adjuvant X metronomic CT in TNBC. In 
this study, which is still recruiting participants, patients with early 
TNBC are randomized to treatment with standard adjuvant CT 
alone or standard adjuvant CT followed by 1 year of X metronomic 
therapy 650 mg/m2 BID. No published data are yet available. 
Biological Agents in the Adjuvant Treatment of TNBC
In another effort to evaluate the benefit of maintenance treat-
ment for TNBC patients, the BEATRICE study [24] enrolled 1,290 
patients to receive CT alone and 1,301 to receive bevacizumab (B) 
plus CT between 3 December 2007 and 8 March 2010. Most pa-
tients received anthracycline-containing therapy; 1,638 (63%) of 
the 2,591 patients had node-negative BC. At the time of analysis for 
invasive DFS (IDFS), median follow-up was 31.5 months (inter-
quartile range 25.6–36.8) in the CT alone group and 32.0 months 
(27.5–36.9) in the B group. The 3-year IDFS was 82.7% (95% CI 
80.5–85.0) with CT alone and 83.7% (81.4–86.0) with B and CT. 
Hence, there are conflicting results on antitumor activity for CT 
administered for a prolonged time. 
Metronomics in the Adjuvant Treatment of TNBC
The term metronomic CT was first introduced almost 20 years 
ago by Douglas Hanahan following the results of a preclinical study 
published by Jutah Folkman and Nob Kerbel [12, 13].
Chronically administered low-dose cyclophosphamide produces 
apoptosis of endothelial cells in the tumor microvasculature with a 
compromised repair process, which induces a prolonged antiangio-
genic effect [12]. Low-dose methotrexate (M) inhibits endothelial 
cell proliferation in vitro and blocks endothelial cell growth factor-
induced neovascularization in the rabbit cornea assay [14]. 
In the past 15 years, metronomic CT demonstrated clinical ac-
tivity associated with a low incidence of adverse events (AEs) in 
patients with metastatic BC [15]. In 2014, André et al. [16] showed 
that metronomic CT has an immune-stimulatory effect through 
different mechanisms and an effect on tumor-initiating cells and 
on tumor dormancy, and might finally also interfere with the 
clonal evolution of tumors.
The antiangiogenic and pro-immune nature of metronomic CT 
makes TNBC a good candidate for re-induction of tumor dor-
mancy or eradication of residual cancer cells [17].
Table 2 summarizes the results of the principal studies that in-
vestigated the role of a metronomic approach as maintenance 
treatment versus no maintenance after standard adjuvant CT in 
TNBC patients.
Capecitabine in the Adjuvant Treatment of TNBC
Several ongoing trials are addressing the intensification of adju-
vant CT in TNBC patients, either through integration of novel 
agents into the adjuvant setting such as platinum, X, ixabepilone, or 
bevacizumab, or through introduction of maintenance therapy such 
as X (CIBOMA and SYSUCC-001) or bevacizumab (BEATRICE).
Preliminary results of the CREATE-X (JBCRG-04) trial by the 
Japan Breast Cancer Research Group were presented at the 2015 
San Antonio Breast Cancer Symposium [18]. The trial randomized 
910 patients to observation versus 8 cycles of X therapy, and re-
ported improved rates of 2-year DFS (87.3 vs. 80.5%; p = 0.001) 
and OS (96.2 vs. 93.9%; p = 0.086) with X. All of the observed ben-
efit was driven by the improved outcome in the ER- subpopulation 
(n = 296) of the study. 
Chen et al. [19] evaluated the clinical value of X-based combina-
tion adjuvant CT in early BC (EBC). The authors analyzed 8 ran-
domized controlled trials with 14,072 participants. X-based combi-
nation adjuvant CT demonstrated a 16% increase in BC-specific 
survival (BCSS) (hazard ratio (HR) 0.84, 95% confidence interval 
(CI) 0.71–0.98; p = 0.03) in the OS analysis and a 22% improve-
ment in DFS (HR 0.78, 95% CI 0.64–0.96; p = 0.02) in the hormone 
receptor-negative subgroup. However, there were no significant 
differences in DFS (HR 0.96, 95% CI 0.89–1.05; p = 0.38), OS (HR 
0.91, 95% CI 0.82–1.00; p = 0.06), or relapse between X-based and 
X-free combination adjuvant CT. Regarding safety, reduced mye-
losuppression and hand-foot syndrome (HFS) development were 
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After 200 deaths, no difference in OS was noted between the 
groups (HR 0.84, 95% CI 0.64–1.12; p = 0.23). Use of B versus CT 
alone was associated with increased incidences of grade 3 or worse 
hypertension (154 (12%) vs. 8 (1%) patients), severe cardiac events 
occurring at any point during the 18-month safety reporting pe-
riod (19 (1%) vs. 2 (< 0.5%)), and treatment (B, CT, or both) dis-
continuation (256 (20%) vs. 30 (2%)). B cannot be recommended 
as adjuvant treatment in unselected patients with TNBC. Further 
follow-up needs to assess the potential effect of B on OS. 
Based on these data, the use of metronomic X may gain more 
interest due to its low toxicity profile and lower price tag. 
The findings that a subset of TNBC is immunogenic and ac-
tively involves the immune system [25–28] provides a strong ra-
tionale for testing immunotherapies or drugs with an immu-
nomodulatory mechanism of action. Different trials are ongoing to 
establish the role of immune checkpoint inhibitors alone or in 
combination, and of other immunotherapies or CT in TNBC. 
Metronomic CT coupled with anticancer vaccines has also been 
investigated to determine whether this combination could be a 
promising approach. 
Ongoing and planned studies in North America, such as the 
Eastern Cooperative Oncology Group-American College of Radi-
ology Imaging Network (ECOG-ACRIN) EA1131 (NCT02445391) 
and SWOG (Southwest Oncology Group) S1418, are trying to de-
fine the role of X, platinum CT, or immune checkpoint inhibitors 
in patients with no pCR after neoadjuvant treatment. The EA1131 
trial is randomizing patients to either X or carboplatin for 6 cycles. 
The S1418/BR006 trial, conducted jointly by the Southwest Oncol-
ogy Group (SWOG) and the National Surgical Adjuvant Breast 
and Bowel Project/Radiation Therapy Oncology Group/Gyneco-
logic Oncology Group (NRG), is randomizing patients to observa-
tion or 1 year of pembrolizumab adjuvant therapy. 
Conclusion
Further progress is needed to improve the outcome of TNBC 
patients in the adjuvant setting. Post-neoadjuvant strategies need 
further proof of benefit before becoming a standard approach. 
Low-dose maintenance therapy remains an attractive approach for 
additional studies in TNBC because of its low cost and good man-
ageability and tolerability. Future plans should include a study 
evaluating low-dose oral maintenance for those TNBC patients 
who continue to have high-risk disease in the post-adjuvant and 
post-neoadjuvant setting. 
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